Brokerages Set NeuroPace, Inc. (NASDAQ:NPCE) PT at $14.00

NeuroPace, Inc. (NASDAQ:NPCE) has earned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $14.00.

Several brokerages have recently issued reports on NPCE. Wells Fargo & Company cut their target price on shares of NeuroPace from $20.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $18.00 price objective on shares of NeuroPace in a research report on Wednesday, August 14th. Finally, Morgan Stanley dropped their target price on shares of NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a report on Monday, July 15th.

NeuroPace Stock Performance

NASDAQ NPCE opened at $6.61 on Friday. NeuroPace has a 52-week low of $5.73 and a 52-week high of $18.15. The company has a fifty day moving average of $7.11 and a 200-day moving average of $8.62. The company has a market capitalization of $190.16 million, a P/E ratio of -5.55 and a beta of 1.78. The company has a debt-to-equity ratio of 5.97, a quick ratio of 5.47 and a current ratio of 6.37.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.03. The firm had revenue of $19.26 million during the quarter, compared to analyst estimates of $18.30 million. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The company’s revenue was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.36) earnings per share. As a group, equities research analysts predict that NeuroPace will post -1.08 EPS for the current fiscal year.

Institutional Investors Weigh In On NeuroPace

A number of large investors have recently modified their holdings of NPCE. Rhumbline Advisers purchased a new stake in NeuroPace in the second quarter worth about $111,000. Financial Advocates Investment Management lifted its stake in shares of NeuroPace by 50.0% in the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after purchasing an additional 5,000 shares during the period. Hillsdale Investment Management Inc. bought a new stake in shares of NeuroPace during the first quarter valued at approximately $155,000. XTX Topco Ltd grew its stake in NeuroPace by 56.1% in the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after purchasing an additional 8,643 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in NeuroPace in the second quarter worth $257,000. Institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.